PMID- 7662980
OWN - NLM
STAT- MEDLINE
DCOM- 19951012
LR  - 20220408
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 86
IP  - 6
DP  - 1995 Sep 15
TI  - Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of 
      Philadelphia chromosome-positive cells in patients with chronic myelogenous 
      leukemia during treatment.
PG  - 2343-9
AB  - Using Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) 
      as a model, our aim has been to develop a molecular cytogenetic method of high 
      resolution analysis for monitoring the frequency of cells with nonrandom 
      chromosome rearrangements in the bone marrow of patients receiving treatment for 
      hematologic malignancies. Long-term exposure (24 hours) of bone marrow cultures 
      to colcemid (0.1 microgram/mL) maximized a high frequency of metaphase 
      collection. Such preparations were subjected to fluorescence in situ 
      hybridization (FISH) using a 5 Mb probe that overlapped the region of the 
      translocation at chromosome 9q34. This detected the Ph translocation in the 
      resultant large number of overly contracted chromosome spreads. The procedure was 
      validated and verified by studying 70 double-blind marrow samples from patients 
      in different stages of Ph+ CML and from patients with Ph- hematologic 
      malignancies (controls). This hypermetaphase FISH (HMF) method clearly identified 
      Ph+ metaphases and allowed the analysis of 500 hypermetaphases per sample in less 
      than 1 hour after FISH. HMF (1) identified statistically significant differences 
      between the frequencies of Ph+ cells in samples that differed by less than 4%; 
      (2) resolved such differences among patient samples that were all judged 100% Ph+ 
      by standard G-band cytogenetics (CG); (3) resulted in the reclassification of 
      response status in 23% of the patients initially classified by CG; (4) recognized 
      Ph+ cells in 16% of patients characterized as having a complete cytogenetic 
      response and in one patient with an original diagnosis of Ph- CML; and in one 
      patient with an original diagnosis of Ph- CML; and (5) was informative where 
      insufficient metaphases were obtainable for analysis by CG. HMF appears to be 
      uniquely suitable for monitoring the status of patients with CML receiving 
      treatment. It should also be applicable for patients with any hematologic 
      diseases where chromosomal alterations are known and appropriate FISH probes are 
      available.
FAU - Seong, D C
AU  - Seong DC
AD  - Department of Hematology, University of Texas M.D. Anderson Cancer Center, 
      Houston 77030, USA.
FAU - Kantarjian, H M
AU  - Kantarjian HM
FAU - Ro, J Y
AU  - Ro JY
FAU - Talpaz, M
AU  - Talpaz M
FAU - Xu, J
AU  - Xu J
FAU - Robinson, J R
AU  - Robinson JR
FAU - Deisseroth, A B
AU  - Deisseroth AB
FAU - Champlin, R E
AU  - Champlin RE
FAU - Siciliano, M J
AU  - Siciliano MJ
LA  - eng
GR  - CA34936/CA/NCI NIH HHS/United States
GR  - CA49639/CA/NCI NIH HHS/United States
GR  - CA55164/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Azure Stains)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interferon-alpha)
RN  - Z01IVE25KI (Demecolcine)
SB  - IM
MH  - Azure Stains
MH  - Bone Marrow/pathology
MH  - Bone Marrow Examination/*methods
MH  - Chromosome Banding
MH  - Demecolcine/pharmacology
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Interferon-alpha/therapeutic use
MH  - Karyotyping/*methods
MH  - Leukemia/pathology
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/*pathology/therapy
MH  - *Metaphase/drug effects
MH  - Neoplasm, Residual
MH  - *Philadelphia Chromosome
MH  - Single-Blind Method
MH  - Treatment Outcome
MH  - Tumor Cells, Cultured/drug effects
EDAT- 1995/09/15 00:00
MHDA- 1995/09/15 00:01
CRDT- 1995/09/15 00:00
PHST- 1995/09/15 00:00 [pubmed]
PHST- 1995/09/15 00:01 [medline]
PHST- 1995/09/15 00:00 [entrez]
AID - S0006-4971(20)77524-5 [pii]
PST - ppublish
SO  - Blood. 1995 Sep 15;86(6):2343-9.